Lu 29-252

Lu 29-252
Clinical data
Other namesLu-29-252; LU-29252; LU29252; Lu 29–252
Drug classSigma σ2 receptor ligand
Identifiers
  • 1'-(4-spiro[1H-2-benzofuran-3,4'-piperidine]-1'-ylbutyl)spiro[1H-2-benzofuran-3,4'-piperidine]
CAS Number
PubChem CID
PubChem SID
Chemical and physical data
FormulaC28H36N2O2
Molar mass432.608 g·mol−1
3D model (JSmol)
  • C1CN(CCC12C3=CC=CC=C3CO2)CCCCN4CCC5(CC4)C6=CC=CC=C6CO5
  • InChI=1S/C28H36N2O2/c1-3-9-25-23(7-1)21-31-27(25)11-17-29(18-12-27)15-5-6-16-30-19-13-28(14-20-30)26-10-4-2-8-24(26)22-32-28/h1-4,7-10H,5-6,11-22H2
  • Key:AEUZWXWBBOOYMB-UHFFFAOYSA-N

Lu 29-252 is a selective sigma σ2 receptor ligand which was under development for the treatment of anxiety disorders but was never marketed. It reached the preclinical stage of development prior to the discontinuation of its development. The drug was under development by Lundbeck.

References

  1. 1 2 3 "LU 29252". AdisInsight. Springer Nature Switzerland AG. 23 May 1995. Retrieved 22 October 2024.
  2. ↑ "LU-29252". Therapeutic Target Database (TTD). D0T8HU. Retrieved 22 October 2024.
  3. ↑ Gronier B, Debonnel G (March 1999). "Involvement of sigma receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems". European Journal of Pharmacology. 368 (2–3): 183–196. doi:10.1016/s0014-2999(99)00025-4. PMID 10193654.
  4. ↑ Abaimov DA, Kovalev GI (2011). "Sigma receptors as a pharmacological target for neuroprotectors. New horizons of pharmacotherapy of Parkinson disease". Neurochemical Journal. 5 (2). Pleiades Publishing Ltd: 83–91. doi:10.1134/s1819712411010028. ISSN 1819-7124.
  5. ↑ Rousseaux CG, Greene SF (August 2016). "Sigma receptors [σRs]: biology in normal and diseased states". Journal of Receptor and Signal Transduction Research. 36 (4): 327–388. doi:10.3109/10799893.2015.1015737. PMC 4906365. PMID 26056947.